Bis(hydroxamamide)-based bifunctional chelating agent for 99mTc labeling of polypeptides
- PMID: 9893958
- DOI: 10.1021/bc980024j
Bis(hydroxamamide)-based bifunctional chelating agent for 99mTc labeling of polypeptides
Abstract
To develop chelating molecules that provide 99mTc-labeled polypeptides of high in vivo stability and high specific activities under mild reaction conditions, an asymmetrical bis(benzohydroxamamide) compound with an amine group, 4'-aminomethyl-N,N'-trimethylenedibenzohydroxamamide [NH2-C3(BHam)2], was designed and synthesized. The amine residue of NH2-C3(BHam)2 was converted to a maleimide group by reaction with N-succinimidyl-6-maleimidohexanoate, and the conjugation product was coupled to thiol groups of a monoclonal antibody against osteogenic sarcoma (OST7, IgG1) pretreated with 2-iminothiolane to prepare C3(BHam)2-OST7. 99mTc radiolabeling of C3(BHam)2-OST7 was performed by the exchange reaction with [99mTc]glucoheptonate. [99mTc]C3(BHam)2-OST7 was further characterized using directly radioiodinated OST7 ([125I]OST7) and [111In]labeled OST7 with 1-[4-[(5-maleimidopentyl)amidobenzyl]ethylenediamine-N,N, N'N'-tetraacetic acid (EMCS-Bz-EDTA) as references. [99mTc]C3(BHam)2-OST7 was obtained with radiochemical yields of over 94% at protein concentrations as low as 0.2 mg/mL at room temperature for 1 h. [99mTc]C3(BHam)2-OST7 remained stable after incubation in freshly prepared murine plasma and in the presence of cysteine. Similar binding affinities to tumor cells were observed between [99mTc]C3(BHam)2-OST7 and [125I]OST7. When injected into normal mice, [99mTc]C3(BHam)2-OST7 exhibited radioactivity levels in the blood similar to [111In]-EMCS-Bz-EDTA-OST7 up to 24 h postinjection with significantly faster elimination rate of the radioactivity from the liver. In nude mice bearing osteogenic sarcoma, no significant differences were observed in the radioactivity levels in the blood and the tumor between [99mTc]C3(BHam)2-OST7 and [125I]OST7 at 24 h postinjection. These findings indicated that C3(BHam)2 provided 99mTc chelate of high stability at low concentrations even when conjugated to an intact antibody. Such characteristics render bis(hydroxamamide) compounds useful as chelating molecules for preparation of 99mTc-labeled polypeptides.
Similar articles
-
Assessment of radiochemical design of antibodies using an ester bond as the metabolizable linkage: evaluation of maleimidoethyl 3-(tri-n-butylstannyl)hippurate as a radioiodination reagent of antibodies for diagnostic and therapeutic applications.Bioconjug Chem. 1996 Nov-Dec;7(6):628-37. doi: 10.1021/bc960058w. Bioconjug Chem. 1996. PMID: 8950481
-
Assessment of the radiochemical design of antibodies with a metabolizable linkage for target-selective radioactivity delivery.Bioconjug Chem. 1998 Jul-Aug;9(4):497-506. doi: 10.1021/bc970220a. Bioconjug Chem. 1998. PMID: 9667952
-
Reassessment of diethylenetriaminepentaacetic acid (DTPA) as a chelating agent for indium-111 labeling of polypeptides using a newly synthesized monoreactive DTPA derivative.J Med Chem. 1996 Aug 30;39(18):3451-60. doi: 10.1021/jm950949+. J Med Chem. 1996. PMID: 8784442
-
Recent advances in 99mTc radiopharmaceuticals.Ann Nucl Med. 2002 Apr;16(2):79-93. doi: 10.1007/BF02993710. Ann Nucl Med. 2002. PMID: 12043913 Review.
-
Radiolabelled peptides: now and the future.Nucl Med Commun. 1995 Sep;16(9):724-32. Nucl Med Commun. 1995. PMID: 7478404 Review.
Cited by
-
Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.J Cancer Ther. 2011 Mar;2(1):22-39. doi: 10.4236/jct.2011.21004. J Cancer Ther. 2011. PMID: 26229727 Free PMC article.
-
Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.J Cancer Ther. 2012 Oct;3(5A):689-711. doi: 10.4236/jct.2012.325089. J Cancer Ther. 2012. PMID: 26225216 Free PMC article.
-
Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate.Cancer Biother Radiopharm. 2012 Feb;27(1):41-55. doi: 10.1089/cbr.2011.1097. Epub 2011 Dec 22. Cancer Biother Radiopharm. 2012. PMID: 22191802 Free PMC article.
-
Novel Bivalent 99mTc-Complex with N-Methyl-Substituted Hydroxamamide as Probe for Imaging of Cerebral Amyloid Angiopathy.PLoS One. 2016 Sep 30;11(9):e0163969. doi: 10.1371/journal.pone.0163969. eCollection 2016. PLoS One. 2016. PMID: 27689870 Free PMC article.
-
Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine.J Cancer Ther. 2015 Jan;6(1):62-89. doi: 10.4236/jct.2015.61009. J Cancer Ther. 2015. PMID: 25821636 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous